As­traZeneca is pay­ing In­nate Phar­ma at least $242M in near-term cash to sew up rights to mon­al­izum­ab-plus

Just 2 days af­ter rolling out a pos­i­tive snap­shot of ac­tiv­i­ty for its NKG2A im­mune check­point in­hibitor mon­al­izum­ab at ES­MO, In­nate Phar­ma SA (Eu­ronext: $IPH) has struck a rich add-on col­lab­o­ra­tion deal with As­traZeneca, which is bulk­ing up its I/O pipeline in a deal that in­cludes $170 mil­lion in up­front pay­ments, a $72 mil­lion eq­ui­ty deal plus bil­lions in added mile­stone pay­ments cov­er­ing a range of de­vel­op­ment pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER